Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
skin prick test-Roxall Medicina España S.A refers to a group of four biological allergen extracts—derived from the pollens of *Dactylis glomerata* (cocksfoot grass), *Lolium perenne* (perennial ryegrass), *Secale cereale* (rye), and *Olea europaea* (olive tree)—undergoing biological standardization by Roxall Medicina España S.A. These extracts are used for the diagnosis of allergic conditions via skin prick testing and for therapeutic allergen immunotherapy. The standardization process involves determining the Histamine Equivalent Potency (HEP) or Skin Prick Test (SPT) value by comparing the wheal size induced by the extracts to a histamine reference in sensitized individuals, ensuring consistency and safety in clinical use for patients with allergic rhinoconjunctivitis and other inhalant allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on skin prick test-Roxall Medicina España S.A.